Meeting
2018 ASCO Annual Meeting
Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).
Authors
Wolfgang Eiermann
Interdisziplinäres Onkologisches Zentrum München, München, Germany
Wolfgang Eiermann , Hope S. Rugo , Sami Diab , Johannes Ettl , Sara A. Hurvitz , Anthony Goncalves , Kyung-Hun Lee , Louis Fehrenbacher , Rinat Yerushalmi , Lida A. Mina , Miguel Martin , Henri Hubert Roche , Young-Hyuck Im , Denka Markova , Iulia Cristina Tudor , Joanne Lorraine Blum , Alison L. Hannah , Jennifer Keating Litton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
NCT01945775
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1070)
DOI
10.1200/JCO.2018.36.15_suppl.1070
Abstract #
1070
Poster Bd #
151
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial.
First Author: Johannes Ettl
Poster
2021 ASCO Annual Meeting
Assessment of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).
First Author: Joyce O'Shaughnessy
Poster
2020 ASCO Virtual Scientific Program
SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).
First Author: Santiago Escrivá